Biomea Fusion (BMEA) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Talphera (TLPH) has outperformed Biomea Fusion (BMEA) over the past year, losing 41.4% versus a loss of 41.5%. Over five years, TLPH leads with a -94.0% price change compared with -95.2% for BMEA. Biomea Fusion is the larger company by market cap ($41.7 million vs $40.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | TLPH |
|---|---|---|
| Share price | $0.5744 | $0.7852 |
| Market cap | $41.75M | $40.80M |
| 1-day change | -2.38% | +6.25% |
| YTD return | -53.68% | -31.12% |
| 1-year return | -41.51% | -41.40% |
| 5-year return | -95.21% | -93.96% |
| EPS (TTM) | $-0.10 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $28.00K |
| Net income (latest FY) | $-61.80M | $-14.29M |
| Operating margin | — | -48157.14% |
| Net margin | — | -51035.71% |
| 52-week high | $2.24 | $1.57 |
| 52-week low | $0.45 | $0.69 |
| Distance from 52-week high | -74.32% | -49.99% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1118.66% | +298.62% |
| Average volume | 2.22M | 144.13K |
| Shares outstanding | 72.68M | 51.96M |
| Employees | 37 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
BMEA vs TLPH FAQ
Which is bigger, Biomea Fusion or Talphera?
Biomea Fusion (BMEA) is larger, with a market capitalization of $41.75M compared with $40.80M for Talphera (TLPH).
Which stock has performed better over the past year, BMEA or TLPH?
TLPH returned -41.40% over the past 12 months, compared with -41.51% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.